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overload (DIOS) were enrolled in their study, rather
than individuals with nonalcoholic steatohepatitis
(NASH). The patients with DIOS were selected on the
basis of serum ferritin levels >400 lg/L, hepatic iron
concentration assessed by magnetic resonance imaging
>50 lmol/g, and body mass index >27 kg/m2. Accord-
ingly, advanced iron overload is required for a diagnosis
of DIOS. In contrast, in our study, only four of the
patients with NASH meet these criteria. The remainder
of the patients with NASH in our study do not meet
their criteria of DIOS. In general, mild or moderate
degrees of hepatic iron accumulation are common in
patients with NASH. Because we did not observe
increased duodenal absorption in our four patients with
NASH and DIOS, we agree that iron absorption was
lower in patients with DIOS than in lean and overweight
controls without iron overload. Overall, we suggest that
patients with DIOS exhibit a different pattern of iron
absorption from those with NASH.
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Bile Acids and Nonalcoholic Fatty Liver Disease: An Intriguing
Relationship
TO THE EDITOR:
Nonalcoholic fatty liver disease stands nowadays as a
leading cause of progressive impairment of liver
function.
We read with great interest the paper by Nagahashi
et al.(1) recently published in Hepatology which high-
lights the role of conjugated bile acids, sphingosine-1
phosphate receptor 2, and sphingosine kinase 2 in reg-
ulating hepatic lipid metabolism and liver lipid con-
tent. Such results are exciting and stimulating.
The role of bile acids in the modulation of hepatic lipid
metabolism is interesting and controversial; previous evi-
dence by Watanabe et al.(2) showed an inhibitory effect of
bile acids on lipogenesis, which was attributed to activa-
tion of the farnesoid X receptor (FXR)–small heterodimer
partner (SHP) axis and consequent depression of the liver
X receptor (LXR)-a–sterol regulatory element binding
protein (SREBP) 1c lipogenic pathway. Evidence from
our research group has shown that both exogenous
administration of bile acids and endogenous exposure to
bile acid overload (as in cholestasis) may reduce hepatic
fat accumulation in rat models, although by different
mechanisms(3): (1) by activating of the FXR-SHP axis and
(2) by inducing cytochrome P450 7A1, which leads to
reduced oxysterol hepatic bioavailability and in turn down-
regulation of the LXR-a–controlled lipogenic pathway.
The ﬁndings in the paper by Nagahashi et al.(1) are
quite surprising, showing the development of fatty liver
disease in SphK2–/– mice in association with decreased
expression of SREBP 1c and lipogenic enzymes like FAS.
As the authors comment, hepatic fat accumulation might
be induced by mechanisms different from increased lipo-
genesis, such as the reduction of lipid and lipoprotein out-
put from the liver, according to previous evidence in
humans.(4) Data from our group are consistent with this
hypothesis. Indeed, we detected a beneﬁcial effect of cho-
lic acid feeding in the choline-deﬁcient dietary model (in
which hepatic lipid export is reduced) but not in the high-
fat model.(2) In other words, the metabolic effects of bile
acids on hepatic lipid metabolism seem to be strictly
dependent on the experimental model utilized to induce
fat liver accumulation as well as on the modality of bile
acid exposure (exogenous versus endogenous) and the rel-
ative activation of the LXR and FXR pathways.
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Experimental evidence like that brought by Nagaha-
shi et al.(1) may bring an enormous contribution to this
ﬁeld, in the perspective of novel pharmacological tar-
gets for the treatment of nonalcoholic fatty liver
disease.
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REPLY:
We thank Carulli et al. for their great interest in our
recent study and insightful comments on bile acid–
mediated regulation of lipid metabolism.(1) Our study
clearly shows that sphingosine-1 phosphate receptor 2
(S1PR2), which is activated by conjugated bile acids,
regulates nuclear sphingosine kinase 2, allowing for the
up-regulation of genes involved in lipid and sterol
metabolism by an epigenetic mechanism.(1) Conju-
gated bile acid–mediated activation of S1PR2 may
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FIG. 1. Role of sphingosine 1-phosphate
receptor 2 in the regulation of hepatic
metabolism. Abbreviations: CBA, conju-
gated bile acid; ERK, extracellular signal–
regulated kinase; FXR, farnesoid X recep-
tor; PDK, pyruvate dehyrdrogenase kinase;
PKC, protein kinase C; SHP, small hetero-
dimer partner; SphK2, sphingosine kinase
2; S1PR2, sphingosine-1 phosphate recep-
tor 2; VLDL, very low-density lipoprotein.
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